| Javier Garcia, MD | |
|
306 Hospital Dr, South Williamson, KY 41503-4095 | |
| (606) 237-1790 | |
| Not Available |
| Full Name | Javier Garcia |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 25 Years |
| Location | 306 Hospital Dr, South Williamson, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932309838 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 41009 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baylor Scott & White Medical Center-white Rock | Dallas, TX | Hospital |
| Entity Name | Longview Wellness Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942269493 PECOS PAC ID: 1254367766 Enrollment ID: O20050714001046 |
News Archive
The Icahn School of Medicine at Mount Sinai has launched an international clinical trial called TWILIGHT to test the safety and effectiveness of treating coronary stent patients with the anti-clotting medication ticagrelor alone, instead of combining it with aspirin, which is the current standard of care. Researchers will analyze the potential benefits of administering ticagrelor to reduce clotting while at the same time reducing the risk of bleeding associated with the use of both medications.
Kerr Corporation, a leading manufacturer of innovative dental restorative materials, has announced the launch of its new Nexus RMGI, a unique dental cement that combines One-Peel™ cleanup, outstanding durability, and improved esthetic qualities for consistent, predictable outcomes.
A new study by researchers at The Hebrew University of Jerusalem in Israel reports the discovery of a promising group of E channel inhibitors with significant antiviral activity. This could be developed into new treatment agents for this often-deadly virus.
Novocure reported today that patients with advanced non-small cell lung cancer (NSCLC) achieved a significant increase in survival time when tumor treating fields (TTF) therapy was added to chemotherapy, as compared to previously reported outcomes for patients receiving chemotherapy alone.
› Verified 8 days ago
| Entity Name | Obhg Texas Holdings Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083917769 PECOS PAC ID: 3577713072 Enrollment ID: O20121018000279 |
News Archive
The Icahn School of Medicine at Mount Sinai has launched an international clinical trial called TWILIGHT to test the safety and effectiveness of treating coronary stent patients with the anti-clotting medication ticagrelor alone, instead of combining it with aspirin, which is the current standard of care. Researchers will analyze the potential benefits of administering ticagrelor to reduce clotting while at the same time reducing the risk of bleeding associated with the use of both medications.
Kerr Corporation, a leading manufacturer of innovative dental restorative materials, has announced the launch of its new Nexus RMGI, a unique dental cement that combines One-Peel™ cleanup, outstanding durability, and improved esthetic qualities for consistent, predictable outcomes.
A new study by researchers at The Hebrew University of Jerusalem in Israel reports the discovery of a promising group of E channel inhibitors with significant antiviral activity. This could be developed into new treatment agents for this often-deadly virus.
Novocure reported today that patients with advanced non-small cell lung cancer (NSCLC) achieved a significant increase in survival time when tumor treating fields (TTF) therapy was added to chemotherapy, as compared to previously reported outcomes for patients receiving chemotherapy alone.
› Verified 8 days ago
| Entity Name | White Rock Ob/gyn Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821340886 PECOS PAC ID: 6305090929 Enrollment ID: O20130207000373 |
News Archive
The Icahn School of Medicine at Mount Sinai has launched an international clinical trial called TWILIGHT to test the safety and effectiveness of treating coronary stent patients with the anti-clotting medication ticagrelor alone, instead of combining it with aspirin, which is the current standard of care. Researchers will analyze the potential benefits of administering ticagrelor to reduce clotting while at the same time reducing the risk of bleeding associated with the use of both medications.
Kerr Corporation, a leading manufacturer of innovative dental restorative materials, has announced the launch of its new Nexus RMGI, a unique dental cement that combines One-Peel™ cleanup, outstanding durability, and improved esthetic qualities for consistent, predictable outcomes.
A new study by researchers at The Hebrew University of Jerusalem in Israel reports the discovery of a promising group of E channel inhibitors with significant antiviral activity. This could be developed into new treatment agents for this often-deadly virus.
Novocure reported today that patients with advanced non-small cell lung cancer (NSCLC) achieved a significant increase in survival time when tumor treating fields (TTF) therapy was added to chemotherapy, as compared to previously reported outcomes for patients receiving chemotherapy alone.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Javier Garcia, MD 1110 N Buckner Blvd, Ste 103, Dallas, TX 75218-3498 Ph: (606) 487-7503 | Javier Garcia, MD 306 Hospital Dr, South Williamson, KY 41503-4095 Ph: (606) 237-1790 |
News Archive
The Icahn School of Medicine at Mount Sinai has launched an international clinical trial called TWILIGHT to test the safety and effectiveness of treating coronary stent patients with the anti-clotting medication ticagrelor alone, instead of combining it with aspirin, which is the current standard of care. Researchers will analyze the potential benefits of administering ticagrelor to reduce clotting while at the same time reducing the risk of bleeding associated with the use of both medications.
Kerr Corporation, a leading manufacturer of innovative dental restorative materials, has announced the launch of its new Nexus RMGI, a unique dental cement that combines One-Peel™ cleanup, outstanding durability, and improved esthetic qualities for consistent, predictable outcomes.
A new study by researchers at The Hebrew University of Jerusalem in Israel reports the discovery of a promising group of E channel inhibitors with significant antiviral activity. This could be developed into new treatment agents for this often-deadly virus.
Novocure reported today that patients with advanced non-small cell lung cancer (NSCLC) achieved a significant increase in survival time when tumor treating fields (TTF) therapy was added to chemotherapy, as compared to previously reported outcomes for patients receiving chemotherapy alone.
› Verified 8 days ago